Immunotherapy improves outcomes of advanced endometrial cancer
https://www.facingourrisk.org/XRAY/immunotherapy-improves-advanced-endometrial-cancer-outcomes
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312
Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone. (Posted 12/4/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is my endometrial cancer considered advanced?
- Have you tested my cancer for biomarkers that may help guide treatment?
- If so, what were my results?
- If not, are there any tests that might be helpful for me?
- Is Keytruda plus chemotherapy an option for me?
Open Clinical Trials
The following studies are enrolling people with advanced endometrial cancer.
- NCT04486352: A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer. This study tests the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab in people with recurrent endometrial cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study evaluates the safety, effectiveness and tolerability of the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability-high (MSI-H) solid tumors resistant to prior PD-(L)1 therapy.
- NCT03955978: Dostarlimab in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer. This study evaluates dostarlimab compared to standard-of-care radiation therapy for patients with inoperable endometrial cancer to establish the safety and efficacy of inducing an anti-tumor immune response.
Several other clinical trials for patients with endometrial cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.